Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia

Summary

To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.

Timeline

Start

2022-03-04

Primary completion

2023-05-01

Completion

2023-05-01

Outcome

Outcome not reported

Stopped: “No patients COVID-19 morbidity decreased.”

Drugs

Indications